Literature DB >> 10488363

The use of dexamethasone in women with preterm premature rupture of membranes--a multicentre, double-blind, placebo-controlled, randomised trial. Dexiprom Study Group.

R C Pattinson1, J D Makin, M Funk, S D Delport, A P Macdonald, K Norman, G Kirsten, C Stewart, D Woods, G Moller, E Coetzee, P Smith, J Anthony, M Schoon, S Grobler.   

Abstract

OBJECTIVE: To assess whether administration of dexamethasone in women with preterm premature rupture of membranes (PPROM) has an effect on the prevalence of maternal sepsis, neonatal respiratory distress syndrome (RDS), perinatal mortality and neonatal sepsis in a developing country.
SETTING: Six public hospitals in South Africa that deal mainly with indigent women.
METHOD: A multicentre, double-blind, placebo-controlled, randomised trial was performed on women with PPROM and fetuses of 28-34 weeks' gestation or clinically estimated fetal weight between 1,000 and 2,000 g if the gestational age was unknown. Women were randomised to receive either dexamethasone 24 mg intramuscularly or placebo in two divided doses 24 hours apart. All women received amoxycillin and metronidazole and were managed expectantly. Hexoprenaline was administered if contractions occurred within the first 24 hours after admission to the trial. OUTCOME MEASURES: The maternal outcome measures were clinical chorio-amnionitis and postpartum sepsis. The outcome measures for infants were perinatal death, RDS, mechanical ventilation, necrotising enterocolitis, and neonatal infection within 72 hours.
RESULTS: One hundred and two women who delivered 105 babies were randomised to the dexamethasone group and 102 women who delivered 103 babies, to the placebo group. The groups were well balanced with regard to clinical features. There was a trend towards fewer perinatal deaths in the dexamethasone group: 4 compared with 10 (P = 0.16, odds ratio 0.37, 95% confidence intervals 0.09-1.34). A subanalysis of mothers who delivered more than 24 hours after admission to the study and their infants revealed a significant reduction in perinatal deaths; 1 death in the dexamethasone group and 7 in the placebo group, P = 0.047 (Fisher's exact test). No woman in either group developed severe sepsis, and the incidence of sepsis in the women did not differ significantly. Eleven infants in each group developed sepsis.
CONCLUSION: This is the first randomised trial in women with PPROM to compare the effects of the use of corticosteroids with placebo, where all women received prophylactic antibiotics concomitantly with the corticosteroids. A trend towards an improved perinatal outcome was demonstrated in the women who received dexamethasone. There was no increased risk of infection in the women or their infants where dexamethasone was administered. Administration of corticosteroids to women with PPROM has more advantages than disadvantages in developing countries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488363

Source DB:  PubMed          Journal:  S Afr Med J


  11 in total

1.  A conference report on prenatal corticosteroid use in low- and middle-income countries.

Authors:  Elizabeth M McClure; Joseph de Graft-Johnson; Alan H Jobe; Steve Wall; Marge Koblinsky; Allisyn Moran; Linda L Wright; Winifride Mwebesa; Marion Koso-Thomas; Robert L Goldenberg
Journal:  Int J Gynaecol Obstet       Date:  2011-09-17       Impact factor: 3.561

2.  Neonatal Morbidities among Moderately Preterm Infants with and without Exposure to Antenatal Corticosteroids.

Authors:  Sanjay Chawla; Girija Natarajan; Dhuly Chowdhury; Abhik Das; Michele Walsh; Edward F Bell; Abbot R Laptook; Krisa Van Meurs; Carl T D'Angio; Barbara J Stoll; Sara B DeMauro; Seetha Shankaran
Journal:  Am J Perinatol       Date:  2018-04-27       Impact factor: 1.862

Review 3.  Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth.

Authors:  Judith Mwansa-Kambafwile; Simon Cousens; Thomas Hansen; Joy E Lawn
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

Review 4.  Reducing neonatal mortality and respiratory distress syndrome associated with preterm birth: a scoping review on the impact of antenatal corticosteroids in low- and middle-income countries.

Authors:  Stanley Mwita; Mary Jande; Deogratias Katabalo; Benjamin Kamala; Deborah Dewey
Journal:  World J Pediatr       Date:  2021-01-03       Impact factor: 2.764

Review 5.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Devender Roberts; Julie Brown; Nancy Medley; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2017-03-21

6.  Association of Neurodevelopmental Outcomes and Neonatal Morbidities of Extremely Premature Infants With Differential Exposure to Antenatal Steroids.

Authors:  Sanjay Chawla; Girija Natarajan; Seetha Shankaran; Athina Pappas; Barbara J Stoll; Waldemar A Carlo; Shampa Saha; Abhik Das; Abbot R Laptook; Rosemary D Higgins
Journal:  JAMA Pediatr       Date:  2016-12-01       Impact factor: 16.193

7.  What really causes necrotising enterocolitis?

Authors:  Thomas Peter Fox; Charles Godavitarne
Journal:  ISRN Gastroenterol       Date:  2012-12-17

8.  Australasian randomised trial to evaluate the role of maternal intramuscular dexamethasone versus betamethasone prior to preterm birth to increase survival free of childhood neurosensory disability (A*STEROID): study protocol.

Authors:  Caroline A Crowther; Jane E Harding; Philippa F Middleton; Chad C Andersen; Pat Ashwood; Jeffrey S Robinson
Journal:  BMC Pregnancy Childbirth       Date:  2013-05-03       Impact factor: 3.007

9.  Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.

Authors:  Emma McGoldrick; Fiona Stewart; Roses Parker; Stuart R Dalziel
Journal:  Cochrane Database Syst Rev       Date:  2020-12-25

Review 10.  Born too soon: care during pregnancy and childbirth to reduce preterm deliveries and improve health outcomes of the preterm baby.

Authors:  Jennifer Requejo; Mario Merialdi; Fernando Althabe; Matthais Keller; Joanne Katz; Ramkumar Menon
Journal:  Reprod Health       Date:  2013-11-25       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.